Curis, Inc. (NASDAQ:CRIS)

CAPS Rating: 4 out of 5

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.


Player Avatar waderjw (62.86) Submitted: 7/14/2011 10:54:21 AM : Outperform Start Price: $3.90 CRIS Score: -110.93

They're having good trial runs on their cancer drugs.

Featured Broker Partners